Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | ELANE | P08246 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13378442 | 1.00 | PREP (0.49) | PREPSMN1; SMN2NPC1RAB9AELANE | |
| SCHEMBL2886001 | 1.00 | PREP (0.49) | PREPSMN1; SMN2NPC1RAB9AELANE | |
| SCHEMBL24438696 | 0.85 | PREP (0.55) | PREPSMN1; SMN2NPC1RAB9A | |
| SCHEMBL3713827 | 0.80 | CYP2C19 (0.48) | PREPSMN1; SMN2NPC1RAB9AELANE | |
| SCHEMBL3823845 | 0.79 | NPC1 (0.50) | SMN1; SMN2NPC1RAB9AELANECYP2C19 | |
| SCHEMBL13073095 | 0.79 | HTR2C (0.52) | SMN1; SMN2NPC1RAB9ACYP2C19PARP1 | |
| SCHEMBL1643399 | 0.79 | HTR2C (0.52) | SMN1; SMN2NPC1RAB9ACYP2C19PARP1 | |
| SCHEMBL29906748 | 0.78 | PARP1 (0.49) | SMN1; SMN2NPC1RAB9AELANECYP2C19 | |
| SCHEMBL23478113 | 0.78 | PSEN1 (0.62) | SMN1; SMN2NPC1RAB9AELANECYP2C19 | |
| SCHEMBL25385249 | 0.78 | SMN1; SMN2 (0.49) | PREPSMN1; SMN2NPC1RAB9AELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100099673-A1 | DECAHYDROQUINOLINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | MERCK SHARP & DOHME CORP. | 2010-04-22 | — | — | US | disclosed |
| US-20100099673-A1 | DECAHYDROQUINOLINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | MERCK SHARP & DOHME CORP. | 2010-04-22 | — | — | US | disclosed |
| WO-2008088744-A1 | DECAHYDROQUINOLINE ANALOGS AS CB2 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099673-A1 | DECAHYDROQUINOLINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | CNR2, CNR1, TRPV1 | PREP 3486/4885SMN1; SMN2 4345/4885NPC1 857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.